We reviewed the medical records of patients with well-differentiated thyroid cancer who were treated with
131I in our hospital between 1995 and 2009. A total of 462 patients were identified. Among these, 81 had metastatic bone lesions at the time of initial
131I therapy (52 had bone metastases alone and the remaining 29 also had metastases in other organs). Median age at the time of treatment was 63 years and the male-to-female ratio was 31:50. Histologically, 56 cases were follicular adenocarcinoma, 14 cases were papillary adenocarcinoma, and 11 cases were other types. The median amount of
131I in each treatment was 100 mCi (range, 50-200 mCi). Sixty-four cases (79%) showed concentration of
131I in metastatic lesions. The 5-year survival rate and median survival of cases with
131I concentration were 59% and 7.8 years, respectively, and those of cases without
131I concentration were 28% and 3.2 years, respectively (p=0.0007). Among cases with
131I concentration, the 5-year survival rate was 76% for patients who had only bone metastases, compared to 17% for patients with additional metastases in other organs (p < 0.0001). The 5-year survival rate was 71% for those who had ≤4 bone metastases, compared to 38% for those with ≥5 bone metastases (p=0.008). The 5-year survival rate was 74% for patients with initial serum thyroglobulin level <10,000 ng/ml, compared to 34% for those with initial serum thyroglobulin level ≥10,000 ng/ml. Therapy with
131I might improve the prognosis of patients with bone metastases from well-differentiated thyroid cancer. Patients without metastases in other organs, with oligometastases, and with low initial thyroglobulin level show more favorable prognoses.
View full abstract